Psoriatic Arthritis, Rheumatoid Arthritis
Conditions
Brief summary
Proportion of patients who achieve disease remission at week 24 will be the primary endpoint. Remission will be defined by: • Clinical Disease Activity Index (CDAI) 2.8 or < 2.8 in RA • DAPSA <4 in PsA.
Detailed description
To provide proof-of-principle validation of the efficacy of combining TNF and IL-6 inhibitors achieve higher remission than current therapies in RA and PsA., To provide preliminary safety and tolerability data on the selected combination therapy and improvement in disease activity as measured by validated outcome measures.
Interventions
Sponsors
Cardiff University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who achieve disease remission at week 24 will be the primary endpoint. Remission will be defined by: • Clinical Disease Activity Index (CDAI) 2.8 or < 2.8 in RA • DAPSA <4 in PsA. | — |
Secondary
| Measure | Time frame |
|---|---|
| To provide proof-of-principle validation of the efficacy of combining TNF and IL-6 inhibitors achieve higher remission than current therapies in RA and PsA., To provide preliminary safety and tolerability data on the selected combination therapy and improvement in disease activity as measured by validated outcome measures. | — |
Countries
Spain
Outcome results
None listed